Per Pfeiffer

List of Publications by Year in Descending Order

140 papers	2,556 citations	26 h-index	47 g-index
153 ext. papers	3,385 ext. citations	4.7 avg, IF	5.01 L-index

#	Paper	IF	Citations
140	-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.. *Frontiers in Oncology*, **2022**, 12, 826073	5.3	1
139	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. *British Journal of Cancer*, **2021**,	8.7	2
138	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer: Analysis of the prognostic effect of serum vitamin D on pancreatic cancer: Several confounders. *European Journal of Cancer*, **2021**, 158, 248-250	7.5	
137	New use for old drugs: Epirubicin in colorectal cancer. *Acta Oncologica*, **2021**, 60, 954-956	3.2	1
136	Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. *Cancers*, **2021**, 13,	6.6	7
135	Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. *Pancreatology*, **2021**, 21, 530-543	3.8	1
134	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. *International Journal of Cancer*, **2021**, 149, 1385-1397	7.5	1
133	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study. *Cancers*, **2021**, 13,	6.6	3
132	Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.. *Journal of Clinical Oncology*, **2021**, 39, e16228-e16228	2.2	1
131	Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8). *Journal of Geriatric Oncology*, **2021**, 12, 1270-1276	3.6	2
130	Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. *Journal of Clinical Pathology*, **2021**, 74, 19-24	3.9	3
129	Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy - a prospective, clinical study. *Journal of Geriatric Oncology*, **2021**, 12, 578-584	3.6	2
128	Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.. *Journal of Clinical Oncology*, **2021**, 39, 44-44	2.2	3
127	How to select cancer patients for immunotherapy. *EBioMedicine*, **2021**, 63, 103184	8.8	
126	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. *European Journal of Cancer*, **2021**, 144, 72-80	7.5	8
125	Predictive value of geriatric oncology screening and geriatric assessment of older patients with cancer: A randomized clinical trial protocol (PROGNOSIS-RCT). *Journal of Geriatric Oncology*, **2021**,	3.6	1
124	Capecitabine in combination with panitumumab is not the treatment of choice in older patients with metastatic colorectal cancer. *Journal of Geriatric Oncology*, **2021**,	3.6	0

123	Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. *Acta Oncologica*, **2021**, 1-9	3.2	1
122	CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better Mutated and a Worse Mutated Subgroup. *Frontiers in Oncology*, **2020**, 10, 8	5.3	13
121	TAS-102 plus bevacizumab in metastatic colorectal cancer - AuthorsSreply. *Lancet Oncology, The*, **2020**, 21, e227	21.7	
120	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. *European Journal of Cancer*, **2020**, 129, 50-59	7.5	7
119	Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. *BMC Cancer*, **2020**, 20, 105	4.8	14
118	TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 412-420	21.7	69
117	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.. *Journal of Clinical Oncology*, **2020**, 38, 7037-7037	2.2	2
116	Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. *Histology and Histopathology*, **2020**, 35, 811-825	1.4	6
115	A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, TPS4664-TPS4664	2.2	
114	Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. *European Journal of Surgical Oncology*, **2020**, 46, 155-159	3.6	16
113	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 176-184	4	5
112	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. *Acta Oncologica*, **2020**, 59, 417-426	3.2	11
111	Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. *European Journal of Cancer Care*, **2020**, 29, e13219	2.4	9
110	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. *Acta Oncologica*, **2020**, 59, 284-290	3.2	3
109	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. *Acta Oncologica*, **2020**, 59, 1016-1023	3.2	2
108	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
107	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. *JAMA Oncology*, **2020**, 6, 1733-1740	13.4	29
106	Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. *International Journal of Cancer*, **2020**, 146, 2913-2922	7.5	19

105	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. *International Journal of Cancer*, **2020**, 148, 2542	7.5	1
104	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. *New England Journal of Medicine*, **2019**, 381, 1632-1643	59.2	481
103	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. *Cancer Treatment Reviews*, **2019**, 77, 1-10	14.4	26
102	Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. *Cancer Medicine*, **2019**, 8, 3623-3635	4.8	23
101	A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. *Acta Oncologica*, **2019**, 58, 1149-1157	3.2	16
100	The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. *Acta Oncologica*, **2019**, 58, 864-871	3.2	14
99	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 376-388	18.8	20
98	How to select colorectal cancer patients for personalized therapy. *EBioMedicine*, **2019**, 41, 36-37	8.8	2
97	Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC). *Journal of Clinical Pathology*, **2019**, 72, 368-372	3.9	6
96	Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. *Journal of Clinical Pathology*, **2019**, 72, 762-770	3.9	4
95	The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).. *Journal of Clinical Oncology*, **2019**, 37, TPS3616-TPS3616	2.2	2
94	Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 637-637	2.2	6
93	QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy: Results from the TASCO1 phase II study.. *Journal of Clinical Oncology*, **2019**, 37, 676-676	2.2	2
92	The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).. *Journal of Clinical Oncology*, **2019**, 37, TPS722-TPS722	2.2	1
91	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncology*, **2019**, 5, 546-550	13.4	225
90	The changing face of treatment for metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2019**, 19, 61-70	3.5	8
89	Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. *Journal of Gastroenterology*, **2019**, 54, 108-121	6.9	8
88	Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. *Clinical Nutrition*, **2019**, 38, 182-190	5.9	35

87	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. *Cancer Chemotherapy and Pharmacology*, **2018**, 81, 573-578	3.5	7
86	Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. *Acta Oncologica*, **2018**, 57, 1057-1062	3.2	15
85	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. *British Journal of Cancer*, **2018**, 118, 1609-1616	8.7	31
84	Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918777036	5.4	42
83	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. *Journal of Clinical Oncology*, **2018**, 36, 4049-4049	2.2	8
82	ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin bevacizumab in patients with metastasizing colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 838-838	2.2	
81	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.. *Journal of Clinical Oncology*, **2018**, 36, 267-267	2.2	
80	Prognostic significance of SATB1 expression in metastatic colorectal cancer: A Nordic prospective cohort study.. *Journal of Clinical Oncology*, **2018**, 36, 707-707	2.2	
79	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.. *Journal of Clinical Oncology*, **2018**, 36, e16249-e16249	2.2	0
78	Expression of podocalyxin-like protein and epidermal growth factor receptor in metastatic colorectal cancer: Prognostic impact and relationship with response to cetuximab.. *Journal of Clinical Oncology*, **2018**, 36, e15587-e15587	2.2	
77	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx): a placebo-controlled randomised phase II study (PLIANT). *Acta Oncologica*, **2018**, 57, 393-402	3.2	52
76	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 395-405	5.1	5
75	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients - study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study. *Pleura and Peritoneum*, **2018**, 3, 20180107	2	12
74	Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy - PIPAC-OPC2. *Pleura and Peritoneum*, **2018**, 3, 20180108	2	16
73	Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure. *Pleura and Peritoneum*, **2018**, 3, 20180128	2	17
72	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. *Tumor Biology*, **2018**, 40, 1010428318811207	2.9	8
71	Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. *Supportive Care in Cancer*, **2017**, 25, 2179-2185	3.9	12
70	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. *BMC Cancer*, **2017**, 17, 48	4.8	11

69	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. *British Journal of Cancer*, **2017**, 116, 1271-1278	8.7	38
68	Risk factors for brain metastases in patients with metastatic colorectal cancer. *Acta Oncologica*, **2017**, 56, 639-645	3.2	20
67	Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Clinical and Experimental Metastasis*, **2017**, 34, 309-314	4.7	43
66	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. *European Journal of Cancer*, **2017**, 81, 26-35	7.5	6
65	S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. *Acta Oncologica*, **2017**, 56, 46-51	3.2	2
64	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. *BMC Cancer*, **2017**, 17, 548	4.8	6
63	Can we ave the rectum by watchful waiting or ransnal microsurgery following (chemo) adiotherapy versus otal mesorectal excision for early ctal ancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. *BMJ Open*, **2017**, 7, e019474	3	50
62	Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naive patients with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2017**, 35, 10032-10032	2.2	1
61	The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, e15131-e15131	2.2	1
60	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. *PLoS ONE*, **2017**, 12, e0182512	3.7	14
59	The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, e15060-e15060	2.2	
58	Trends in colorectal cancer in the elderly in Denmark, 1980-2012. *Acta Oncologica*, **2016**, 55 Suppl 1, 29-39	3.2	25
57	Trends in cancer in the elderly population in Denmark, 1980-2012. *Acta Oncologica*, **2016**, 55 Suppl 1, 1-6	3.2	41
56	Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2016**, 34, 10018-10018	2.2	1
55	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. *Oncotarget*, **2016**, 7, 59441-59457	3.3	5
54	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. *Oncotarget*, **2016**, 7, 75013-75022	3.3	46
53	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. *Oncotarget*, **2016**, 7, 41948-41958	3.3	27
52	FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.. *Journal of Clinical Oncology*, **2016**, 34, 408-408	2.2	

51	S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies.. *Journal of Clinical Oncology*, **2016**, 34, 153-153	2.2	
50	Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final Results.. *Journal of Clinical Oncology*, **2016**, 34, e15725-e15725	2.2	1
49	Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. *Journal of Clinical Oncology*, **2016**, 34, e15115-e15115	2.2	
48	Early F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. *Acta Oncologica*, **2016**, 55, 1175-1182	3.2	3
47	Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example. *ESMO Open*, **2016**, 1, e000021	6	7
46	Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. *Acta Oncologica*, **2016**, 55, 881-5	3.2	6
45	Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980-2012. *Acta Oncologica*, **2016**, 55 Suppl 1, 40-5	3.2	20
44	Trends in upper gastro-intestinal cancer among the elderly in Denmark, 1980-2012. *Acta Oncologica* , **2016**, 55 Suppl 1, 23-8	3.2	5
43	Personalized Clinical Decision Making in Gastrointestinal Malignancies: The Role of PET. *PET Clinics*, **2016**, 11, 273-83	2.2	7
42	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. *BMC Cancer*, **2016**, 16, 91	4.8	22
41	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. *International Journal of Cancer*, **2016**, 139, 2312-24	7.5	23
40	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. *Molecular Oncology*, **2015**, 9, 1169-85	7.9	57
39	Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. *Clinical Colorectal Cancer*, **2015**, 14, 170-6	3.8	18
38	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. *Gut*, **2015**, 64, 921-8	19.2	17
37	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. *European Journal of Cancer*, **2015**, 51, 2678-85	7.5	40
36	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. *International Journal of Cancer*, **2015**, 137, 2470-7	7.5	6
35	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. *PLoS ONE*, **2015**, 10, e0131046	3.7	64
34	Efficacy and safety of S-1 and gemcitabine in an unselected Western cohort of patients with unresectable pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, e15258-e15258	2.2	

33	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. *Journal of Clinical Oncology*, **2015**, 33, 3548-3548	2.2	
32	Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer.. *Journal of Clinical Oncology*, **2015**, 33, e15081-e15081	2.2	
31	A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. *Cancer Treatment Reviews* , **2014**, 40, 701-15	14.4	53
30	miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. *PLoS ONE*, **2014**, 9, e99886	3.7	54
29	A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.. *Journal of Clinical Oncology*, **2014**, 32, 337-337	2.2	3
28	Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. *PLoS ONE*, **2014**, 9, e87746	3.7	15
27	Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. *PLoS ONE*, **2014**, 9, e109430	3.7	37
26	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. *Journal of Clinical Oncology*, **2014**, 32, e14525-e14525	2.2	
25	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. *Journal of Clinical Oncology*, **2014**, 32, 3590-3590	2.2	
24	Trastuzumab with triple chemotherapy (DOC) in patients with advanced gastroesophageal cancer: A phase I dose-finding trial.. *Journal of Clinical Oncology*, **2014**, 32, 108-108	2.2	
23	Outcome after liver transplantation compared with chemotherapy in colorectal cancer patients with nonresectable liver-only disease.. *Journal of Clinical Oncology*, **2014**, 32, 531-531	2.2	
22	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 3572-3572	2.2	1
21	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. *Journal of Clinical Oncology*, **2013**, 31, 392-392	2.2	
20	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. *Journal of Clinical Oncology*, **2013**, 31, 164-164	2.2	
19	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 3597-3597	2.2	
18	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2013**, 31, 3571-3571	2.2	
17	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.. *Journal of Clinical Oncology*, **2012**, 30, 3538-3538	2.2	2
16	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. *Journal of Clinical Oncology*, **2012**, 30, 3548-3548	2.2	

15	Biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastroesophageal cancer (GEC).. *Journal of Clinical Oncology*, **2012**, 30, e14517-e14517	2.2	
14	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. *Cancer*, **2009**, 115, 4679-87	6.4	101
13	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. *OncoTargets and Therapy*, **2009**, 2, 17-27	4.4	3
12	Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. *Acta Oncologica*, **2007**, 46, 697-701	3.2	32
11	High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial. *Acta Oncologica*, **2005**, 44, 224-9	3.2	14
10	Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. *Acta Oncologica*, **2003**, 42, 832-6	3.2	20
9	Patterns of angiogenesis in nonsmall-cell lung carcinoma. *Cancer*, **2001**, 91, 1500-1509	6.4	64
8	Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. *Acta Oncologica*, **1997**, 36, 171-4	3.2	24
7	Re: five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. *Journal of the National Cancer Institute*, **1997**, 89, 1892-3	9.7	7
6	Local recurrence of basal cell carcinoma and cisplatinum containing chemotherapy. *Acta Oncologica* , **1997**, 36, 87	3.2	2
5	Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. *Acta Oncologica*, **1996**, 35, 677-82	3.2	53
4	Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial. *Acta Oncologica*, **1996**, 35, 57-61	3.2	4
3	Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?. *Acta Oncologica*, **1992**, 31, 219-24	3.2	15
2	A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. *Cancer Chemotherapy and Pharmacology*, **1991**, 28, 205-10	3.5	7
1	A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. *Cancer Chemotherapy and Pharmacology*, **1991**, 28, 465-9	3.5	48